20776-54-9Relevant articles and documents
Steck et al.
, p. 1241 (1946)
Novel quinazoline-containing compound, and intermediate and application thereof
-
, (2021/06/12)
The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma
Desbois, Nicolas,Gardette, Maryline,Papon, Janine,Labarre, Pierre,Maisonial, Aurelie,Auzeloux, Philippe,Lartigue, Claire,Bouchon, Bernadette,Debiton, Eric,Blache, Yves,Chavignon, Olivier,Teulade, Jean-Claude,Maublant, Jean,Madelmont, Jean-Claude,Moins, Nicole,Chezal, Jean-Michel
, p. 7671 - 7690 (2008/12/23)
Various iodo-acridone and acridine carboxamides have been prepared and evaluated as agents for targeted radionuclide and/or chemotherapy for melanoma, due to their structural similarity to benzamides which are known to possess specific affinity for melanin. Three of these carboxamides selected for their in vitro cytotoxic properties were radioiodinated with [125I]NaI at high specific activity. Biodistribution studies carried out in B16F0 murine melanoma tumour-bearing mice highlighted that acridone 8f and acridine 9d, presented high, long-lasting tumour concentrations together with an in vivo kinetic profile favourable to application in targeted radionuclide therapy.